ArticleJournal of pharmaceutical policy and practice2025
Barriers to and enablers of Pakistani pharmaceutical export to regulated markets: regulatory perspective.
Article in Journal of pharmaceutical policy and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pharmaceutical sector in Pakistan has grown over a period; however, there are certain barriers within the framework that regulate the growth and export of pharmaceuticals in the country. The purpose of this study was to highlight the current challenges for the pharmaceuticals' export from Pakistan, especially to countries with stringent regulatory authorities (SRAs), from a regulatory perspective, and to identify the facilitators that may help resolve these challenges. Methods: In this qualitative study, data were collected from the participants from the regional offices of Drug Regulatory Authority of Pakistan (DRAP), located in Lahore, Islamabad, and Quetta. Regulatory participants with a minimum experience of 6 years and the designation of an assistant director or above were recruited through purposive sampling. Semi-structured interviews were used to collect information from regulatory experts. Inductive thematic content analysis was employed to conclude the data.Data analysis generated 5 themes and 20 categories/codes. Poor export performance and pharmaceutical growth was attributed to barriers such as: inadequate industrial research and development, non-compliance with the current standards of good manufacturing practices (cGMP), absence of regulatory requirements for high-tech equipment, insufficient academia-industry collaboration, shortage of locally manufactured active pharmaceutical ingredients and lack of support from the government. Accreditation with international organisations such as the World Health Organisation and the Pharmaceutical Inspection Co-operation Scheme was considered deficient. DRAP, in coordination with the Trade Development Authority, could enhance pharmaceutical exports. Addressing the above challenges could boost the export and expand international market share of Pakistani Pharmaceuticals in countries with SRAs. Conclusion: The cGMP compliance, regulatory assistance, and appropriate research and development, including bioequivalence studies, could contribute to export enhancement to SRA countries. Further, the exports from Pakistan to countries with SRAs could be enhanced with DRAP's coordination with the trade development authority of Pakistan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.